Article Details

Monoclonal antibodies challenge marketed small-molecule Alzheimer's dominance

Retrieved on: 2022-12-06 17:05:45

Tags for this article:

Click the tags to see associated articles and topics

Monoclonal antibodies challenge marketed small-molecule Alzheimer's dominance. View article details on hiswai:

Excerpt

Only 22% of all Alzheimer's therapy approvals have been for biologics, with monoclonal antibodies accounting for 11% of these.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up